{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:50:52Z","timestamp":1784152252487,"version":"3.55.0"},"reference-count":20,"publisher":"Society of Nuclear Medicine","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2023,12,20]]},"published-print":{"date-parts":[[2024,3]]},"DOI":"10.2967\/jnumed.123.266614","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T14:05:19Z","timestamp":1709301919000},"page":"409-415","source":"Crossref","is-referenced-by-count":15,"title":["The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy"],"prefix":"10.2967","volume":"65","author":[{"given":"Surekha","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Lawhn-Heath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Paciorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Mirro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily K.","family":"Bergsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,3,1]]},"reference":[{"key":"2024031508451021000_65.3.409.1","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975"},{"key":"2024031508451021000_65.3.409.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0110-y"},{"key":"2024031508451021000_65.3.409.3","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12020-017-1273-x","article-title":"Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms","volume":"58","author":"Leoncini","year":"2017","journal-title":"Endocrine."},{"key":"2024031508451021000_65.3.409.4","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.230607"},{"key":"2024031508451021000_65.3.409.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1902-1"},{"key":"2024031508451021000_65.3.409.6","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00259-014-2788-5","article-title":"Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT)","volume":"41","author":"Kong","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024031508451021000_65.3.409.7","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1200\/JCO.2018.78.5865","article-title":"Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with 177Lu-Dotatate in the phase III NETTER-1 trial","volume":"36","author":"Strosberg","year":"2018","journal-title":"J Clin Oncol."},{"key":"2024031508451021000_65.3.409.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607427"},{"key":"2024031508451021000_65.3.409.9","doi-asserted-by":"crossref","first-page":"e0260073","DOI":"10.1371\/journal.pone.0260073","article-title":"Haematotoxicity during peptide receptor radionuclide therapy: baseline parameters differences and effect on patient\u2019s therapy course","volume":"16","author":"De Vries-Huizing","year":"2021","journal-title":"PLoS ONE."},{"key":"2024031508451021000_65.3.409.10","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.122.264860"},{"key":"2024031508451021000_65.3.409.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.114.148437"},{"key":"2024031508451021000_65.3.409.12","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00259-023-06257-6","article-title":"The relationship between tumour dosimetry, response, and overall survival in patients with unresectable neuroendocrine neoplasms (NEN) treated with 177Lu DOTATATE (LuTate)","volume":"50","author":"Alipour","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024031508451021000_65.3.409.13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40658-017-0193-4","article-title":"Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey","volume":"4","author":"Sj\u00f6green Gleisner","year":"2017","journal-title":"EJNMMI Phys."},{"key":"2024031508451021000_65.3.409.14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40644-022-00467-1","article-title":"Post-PRRT scans: which scans to make and what to look for","volume":"22","author":"Aalbersberg","year":"2022","journal-title":"Cancer Imaging."},{"key":"2024031508451021000_65.3.409.15","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3390\/cancers13050962","article-title":"Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE: differences in tumor dosimetry, vascularity and lesion metrics in pancreatic and small intestinal neuroendocrine neoplasms","volume":"13","author":"Jahn","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2024031508451021000_65.3.409.16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00259-018-4209-7","article-title":"Personalized 177Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial","volume":"46","author":"Del Prete","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024031508451021000_65.3.409.17","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-018-3945-z","article-title":"Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity","volume":"45","author":"Garske-Rom\u00e1n","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024031508451021000_65.3.409.18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/RLU.0000000000003412","article-title":"Clinical assessment of 177Lu-DOTATATE quantification by comparison of SUV-based parameters measured on both post-PRRT SPECT\/CT and 68Ga-DOTATOC PET\/CT in patients with neuroendocrine tumors: a feasibility study","volume":"46","author":"Thuillier","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2024031508451021000_65.3.409.19","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/MNM.0000000000001592","article-title":"Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors","volume":"43","author":"Wong","year":"2022","journal-title":"Nucl Med Commun."},{"key":"2024031508451021000_65.3.409.20","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-011-1937-3"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.266614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T15:46:39Z","timestamp":1710517599000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.266614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":20,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,1]]},"published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.2967\/jnumed.123.266614"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.266614","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]}}}